Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
PBMs profit off expensive niche meds
Pharmacy benefits managers are building lucrative side businesses in specialty drugs, becoming in some cases the sole distributors for certain niche medications. Critics say distributing these drugs--whose prices are rising much faster than other meds'--could conflict with the PBMs' primary mission of keeping overall drug prices down for health insurers.
- read the story in the New York Times
Related Articles:
Specialty-drug spending spawns protest. Specialty drug report
Can specialty drugs turn pharma tide? Drug report
Specialty drugs emerge as key price driver. Drug report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
